Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A

Patients with the severe form of hemophilia A (HA) present with a severe phenotype, and can suffer from life-threatening, spontaneous hemorrhaging. While prophylactic FVIII infusions have revolutionized the clinical management of HA, this treatment is short-lived, expensive, and it is not available...

Full description

Bibliographic Details
Main Authors:	Christopher Stem, Christopher Rodman, Ritu M. Ramamurthy, Sunil George, Diane Meares, Andrew Farland, Anthony Atala, Christopher B. Doering, H. Trent Spencer, Christopher D. Porada, Graça Almeida-Porada
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Cell and Developmental Biology
Subjects:	gene therapy hemophilia A FVIII endothelial progenitor cell mesenchymal stromal (stem) cell therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2021.678117/full

Similar Items

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
by: Nadia El-Akabawy, et al.
Published: (2020-06-01)

Role of B Cells in Breaking and Maintaining Tolerance to Clotting Factor VIII in Congenital and Acquired Hemophilia A
by: Amanda M. Actor, et al.
Published: (2014-04-01)

Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A
by: Melanie Rose, et al.
Published: (2020-06-01)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
by: Brady Trevisan, et al.
Published: (2021-03-01)

Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A
by: Muhammad Elnaggar, et al.
Published: (2020-06-01)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
by: Zhenping Chen, et al.
Published: (2021-03-01)

Gene Therapy in Hemophilia: Recent Advances
by: E. Carlos Rodríguez-Merchán, et al.
Published: (2021-07-01)

Hemophilia A: An Ideal Disease to Correct in Utero
by: Christopher D Porada, et al.
Published: (2014-12-01)

Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice
by: Tischer B, et al.
Published: (2018-03-01)

Repression of factor VIII inhibitor development with apoptotic factor VIII-expressing embryonic stem cells
by: Yoshihiko Sakurai, et al.
Published: (2013-07-01)

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
by: Mario Schiavoni, et al.
Published: (2019-12-01)

Factor VIII-Intron 1 Inversion of Hemophilia A Patients In West Anatolia
by: Pehlivan M, et al.
Published: (2007-04-01)

Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective
by: Daniela Paola Roggeri, et al.
Published: (2020-06-01)

MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA
by: Davide Matino, et al.
Published: (2020-01-01)

Advanced therapies for the treatment of hemophilia: future perspectives
by: Liras Antonio, et al.
Published: (2012-12-01)

Novel Coagulation Factor VIII Gene Therapy in a Mouse Model of Hemophilia A by Lipid-Coated Fe<sub>3</sub>O<sub>4</sub> Nanoparticles
by: Yung-Tsung Kao, et al.
Published: (2021-08-01)

Molecular Characterization of Hemophilia a in Southeast Bulgaria
by: Sukarova Stefanovska E, et al.
Published: (2008-01-01)

FVIII Immunity : early events and tolerance mechanisms to FVIII
by: Qadura, Mohammad Imad
Published: (2008)

Genomic alterations in the F8 gene correlating with severe hemophilia A in Egyptian patients
by: Rehab M. Mosaad, et al.
Published: (2021-02-01)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
by: Linari S, et al.
Published: (2020-05-01)

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects
by: Raimondo De Cristofaro, et al.
Published: (2019-04-01)

Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A— A Systematic Review and Meta-Analysis
by: A. Abdi, et al.
Published: (2020-05-01)

Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII
by: Jenni Firrman, et al.
Published: (2020-06-01)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A
by: Chowdary P, et al.
Published: (2016-09-01)

Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators
by: Ahmad Faisal Karim, et al.
Published: (2020-06-01)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
by: Seema R. Patel, et al.
Published: (2020-04-01)

Acquired hemophilia A: A case report
by: Sarita Pradhan, et al.
Published: (2017-01-01)

Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1
by: Davide Matino, et al.
Published: (2020-04-01)

Past, present and future of hemophilia: a narrative review
by: Franchini Massimo, et al.
Published: (2012-05-01)

Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-γ ELISpot method
by: Kathryn S. Patton, et al.
Published: (2021-09-01)

Relation of bleeding patterns and factor VIII levels in children with hemophilia
by: Rina Rahardiani, et al.
Published: (2016-10-01)

Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective
by: Benson G, et al.
Published: (2021-01-01)

Further Evidence That MicroRNAs Can Play a Role in Hemophilia A Disease Manifestation: F8 Gene Downregulation by miR-19b-3p and miR-186-5p
by: Katarzyna I. Jankowska, et al.
Published: (2020-07-01)

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
by: Batt K, et al.
Published: (2019-06-01)

The Effect of Benson’s Relaxation Technique on Pain Intensity, Belief, Perception, and Acceptance in adult Hemophilia Patients: A Randomized Controlled Trial
by: Zahra Molazem, et al.
Published: (2021-07-01)

Dihydrodiosgenin inhibits endothelial cell-derived factor VIII and platelet-mediated hepatocellular carcinoma metastasis
by: Zhuang M, et al.
Published: (2019-05-01)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
by: Alexandra Sherman, et al.
Published: (2017-11-01)

[Kovaltry® for the replacement therapy in patients with Hemophilia A]
by: Daniela Paola Roggeri, et al.
Published: (2016-06-01)

Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells
by: Sandrine Delignat, et al.
Published: (2020-03-01)

Reprogrammed CD4+ T Cells That Express FoxP3+ Control Inhibitory Antibody Formation in Hemophilia A Mice
by: Roland W. Herzog, et al.
Published: (2019-02-01)

Cannot write session to /tmp/vufind_sessions/sess_1l1oepvql3s9v000fp9jpu7b4t